SCHEMBL21821560

SCHEMBL21821560

CCC(=O)N1CCN(CCNC=C2C(=O)CC(c3ccccc3)CC2=O)CC1

nearest known ligand 0.49

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ MAP1LC3B Q9GZQ8 9/20 0.46
▸ TSHR P16473 2/20 0.46
▸ CYP3A4 P08684 1/20 0.46
▸ CYP2C9 P11712 1/20 0.46
▸ CYP2C19 P33261 1/20 0.46
▸ ALDH1A1 P00352 5/20 0.44
▸ MEN1 O00255 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ MAPT P10636 2/20 0.42
▸ USP2 O75604 1/20 0.41
▸ HTT P42858 1/20 0.41
▸ LMNA P02545 1/20 0.41
▸ BLM P54132 1/20 0.41
▸ KDM1A O60341 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21821987 0.89 CYP2C9 (0.42) MAP1LC3BTSHRCYP3A4CYP2C9CYP2C19
SCHEMBL21821806 0.89 CYP3A4 (0.54) MAP1LC3BTSHRCYP3A4CYP2C9CYP2C19
SCHEMBL21773995 0.87 ALDH1A1 (0.46) MAP1LC3BTSHRCYP3A4CYP2C9CYP2C19
SCHEMBL21821703 0.87 MEN1 (0.42) MAP1LC3BTSHRCYP3A4CYP2C9CYP2C19
SCHEMBL21821755 0.87 MAP1LC3B (0.44) MAP1LC3BTSHRCYP3A4CYP2C9CYP2C19
SCHEMBL21773998 0.86 KMT2A (0.47) ALDH1A1MEN1KMT2A
SCHEMBL26530728 0.86 MEN1 (0.49) MAP1LC3BCYP2C19MEN1KMT2A
SCHEMBL21773997 0.85 ALDH1A1 (0.47) MAP1LC3BALDH1A1MEN1KMT2AMAPT
SCHEMBL21821591 0.85 SLC18A3 (0.50) MAP1LC3BTSHRCYP2C19ALDH1A1MEN1
SCHEMBL21792847 0.83 MEN1 (0.44) MAP1LC3BCYP2C19ALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3632903-B1 COMPOUND USED AS AUTOPHAGY REGULATOR, AND PREPARATION METHOD THEREFOR AND USES THEREOF WIGEN BIOMEDICINE TECH SHANGHAI CO LTD (CN) 2023-10-11 — — EP disclosed
EP-3632903-B1 COMPOUND USED AS AUTOPHAGY REGULATOR, AND PREPARATION METHOD THEREFOR AND USES THEREOF WIGEN BIOMEDICINE TECH SHANGHAI CO LTD (CN) 2023-10-11 — — EP disclosed
US-11319303-B2 Compound used as autophagy regulator, and preparation method therefor and uses thereof Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) 2022-05-03 — — US disclosed
US-11319303-B2 Compound used as autophagy regulator, and preparation method therefor and uses thereof Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) 2022-05-03 — — US disclosed
US-20200190066-A1 COMPOUND USED AS AUTOPHAGY REGULATOR, AND PREPARATION METHOD THEREFOR AND USES THEREOF Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) 2020-06-18 — — US disclosed
US-20200190066-A1 COMPOUND USED AS AUTOPHAGY REGULATOR, AND PREPARATION METHOD THEREFOR AND USES THEREOF Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) 2020-06-18 — — US disclosed
EP-3632903-A1 COMPOUND USED AS AUTOPHAGY REGULATOR, AND PREPARATION METHOD THEREFOR AND USES THEREOF Wigen Biomedicine Technology (Shanghai) Co., Ltd. (CN) 2020-04-08 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11319303-B2 Compound used as autophagy regulator, and preparation method therefor and uses thereof ATG7, SQSTM1, BECN1 MAP1LC3B 15/4885TSHR 4336/4885CYP3A4 2423/4885
US-20200190066-A1 COMPOUND USED AS AUTOPHAGY REGULATOR, AND PREPARATION METHOD THEREFOR AND USES THEREOF ATG7, SQSTM1, BECN1 MAP1LC3B 15/4885TSHR 4336/4885CYP3A4 2423/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback